Literature DB >> 11466143

Value and limitations of ambulatory ECG monitoring for assessment of myocardial ischemia.

D Tzivoni1.   

Abstract

Ambulatory ECG monitoring (AEM) is the only available method to assess the presence and severity of myocardial ischemia during daily life. Several investigators have shown that the recording systems currently used can detect ischemic changes with similar accuracy as treadmill exercise testing. Ischemic changes on AEM are, however, present in only 40%-60% of patients with coronary artery disease (CAD) and positive exercise tests. For this reason, and because of the high day-to-day variability in daily ischemic changes, AEM cannot be used as a screening tool for detecting CAD or for evaluating severity of ischemia in individual patients. In patients with proven CAD, ischemic changes on AEM are associated with an adverse outcome in patients with stable and unstable ischemic syndromes, and in postmyocardial infarction patients. Suppression of daily ischemia seems to be associated with improved outcome. The mechanism of daily ischemia is not identical to exercise-induced ischemia. In addition to increased demand, which is a major contributor to AEM detected-ischemia, increased coronary tone also seems to play a major role. AEM has been shown to be a useful and reliable tool to assess the efficacy of various antiischemic drugs.

Entities:  

Mesh:

Year:  2001        PMID: 11466143      PMCID: PMC7027627          DOI: 10.1111/j.1542-474x.2001.tb00114.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  44 in total

1.  Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.

Authors:  R F Davies; A D Goldberg; S Forman; C J Pepine; G L Knatterud; N Geller; G Sopko; C Pratt; J Deanfield; C R Conti
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

2.  Intermittent ST depression and mortality after myocardial infarction.

Authors:  W Ruberman; R Crow; C R Rosenberg; P M Rautaharju; R E Shore; B S Pasternack
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

3.  Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease.

Authors:  G A Diamond; J S Forrester
Journal:  N Engl J Med       Date:  1979-06-14       Impact factor: 91.245

4.  Anti-ischemic effects of amlodipine in patients with stable angina pectoris and myocardial ischemia during daily life. Amlodipine Study Group.

Authors:  P C Deedwania
Journal:  Am J Cardiol       Date:  1999-04-01       Impact factor: 2.778

5.  Changes in myocardial ischemic threshold during daily activities.

Authors:  S Banai; M Moriel; J Benhorin; A Gavish; S Stern; D Tzivoni
Journal:  Am J Cardiol       Date:  1990-12-15       Impact factor: 2.778

6.  Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial.

Authors:  D Tzivoni; H Kadr; S Braat; W Rutsch; J A Ramires; I Kobrin
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

7.  Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization.

Authors:  D J Patel; H J Purcell; K M Fox
Journal:  Eur Heart J       Date:  1999-01       Impact factor: 29.983

8.  Assessment of ischemic changes by ambulatory ECG-monitoring: comparison with 12-lead ECG during exercise testing.

Authors:  N Samniah; D Tzivoni
Journal:  J Electrocardiol       Date:  1997-07       Impact factor: 1.438

9.  Silent ischemia during daily life is an independent predictor of mortality in stable angina.

Authors:  P C Deedwania; E V Carbajal
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

10.  Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators.

Authors:  R F Davies; H Habibi; W P Klinke; P Dessain; C Nadeau; D C Phaneuf; S Lepage; S Raman; M Herbert; K Foris
Journal:  J Am Coll Cardiol       Date:  1995-03-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.